Format

Send to

Choose Destination
Ann Pediatr Endocrinol Metab. 2017 Mar;22(1):15-26. doi: 10.6065/apem.2017.22.1.15. Epub 2017 Mar 31.

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.

Author information

1
Department of Bioengineering, College of Engineering, and BK21 PLUS Future Biopharmaceutical Human Resources Training and Research Team, Hanyang University, Seoul, Korea.
2
Institute of Nano Science & Technology (INST), Hanyang University, Seoul, Korea.

Abstract

The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary to develop new drugs, one of which is a glucagon-like peptide-1 (GLP-1) based therapy. GLP-1 has been shown to ameliorate diabetes-related conditions by augmenting pancreatic β-cell insulin secretion and having the low risk of causing hypoglycemia. Because of a very short half-life of GLP-1, many researches have been focused on the development of GLP-1 receptor (GLP-1R) agonists with long half-lives such as exenatide and dulaglutide. Now GLP-1R agonists have a variety of dosing-cycle forms to meet the needs of various patients. In this article, we review the physiological features of GLP-1, the effects of GLP-1 on T2D, the features of several GLP-1R agonists, and the therapeutic effect on T2D.

KEYWORDS:

GLP-1R agonist; GLP-1R agonist clinical trials; Glucagon-like peptide-1; Glucagon-like peptide-1 receptor; Type 2 diabetes

Conflict of interest statement

Conflict of interest: No potential conflict of interest relevant to this article was reported.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Publishing M2Community Icon for PubMed Central
Loading ...
Support Center